mkjhOver the past week to two weeks, the stock has shown small fluctuations, mostly trading around $1.00–$1.30 range, with some volatility typical of biotech micro-caps.
The 20-day moving average is ~1.09, and the 200-day average is ~1.16, suggesting recent prices are roughly in line with recent trends.
FATE’s price is well below its 52-week high (~$1.94) and above its 52-week low (~$0.66) — still within that range.
$Fate Therap(FATE.US)
Fate Therapeutics presented updated clinical data at ACR Convergence 2025 showing immune system remodeling and durable responses in patients with systemic lupus erythematosus (SLE) treated with its off-the-shelf FT819 CAR-T cell therapy. This suggests potential benefit in a difficult-to-treat autoimmune condition. $Fate Therap(FATE.US)
Fate Therapeutics has released updated clinical data for its lead off‑the‑shelf CAR T‑cell therapy, FT819, in Phase 1 trials for patients with moderate‑to‑severe systemic lupus erythematosus (SLE). The new results show meaningful and durable reductions in disease activity, including complete renal responses in lupus nephritis patients and sustained improvements with favourable safety profiles, even with less‑intensive or no conditioning chemotherapy. The company is now expanding the trial across additional U.S. and international sites and continues discussions with the U.S. FDA under its Regenerative Medicine Advanced Therapy (RMAT) designation as it plans a pivotal registrational study in 2026.
$Fate Therap(FATE.US)
Its key program, FT819, is an early-stage CAR-T therapy showing encouraging safety and early effectiveness in Phase 1 trials for autoimmune diseases like lupus. Trials are expanding internationally, which helps speed up data collection.
Financially, the company has cash runway into 2027, reducing near-term funding pressure. However, analysts remain neutral (Hold) as commercialization is still years away.
Fate Therapeutics remains a high-risk, high-reward biotech play, with recent developments mainly centred around its cell therapy pipeline, particularly FT819 (off-the-shelf CAR-T) for autoimmune diseases.
